Showing 1 - 5 results of 5 for search 'Himal Lal', query time: 0.05s Refine Results
  1. 1
    Safety and immunogenicity of a Herpes Zoster subunit vaccine in Japanese population aged ≥50 years when administered subcutaneously vs. intramuscularly

    Safety and immunogenicity of a Herpes Zoster subunit vaccine in Japanese population aged ≥50 years when administered subcutaneously vs. intramuscularly by Peter Vink, Masanari Shiramoto, Masayuki Ogawa, Masahiro Eda, Martine Douha, Thomas Heineman, Himal Lal

    Published 2017
    Connect to this object online.
    Book
    Save to List
    Saved in:
  2. 2
    Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults ≥ 50 years of age with a prior history of herpes zoster: A phase III, non-randomized, open-label clinical trial

    Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults ≥ 50 years of age with a prior history of herpes zoster: A phase III, non-randomized, o... by Olivier Godeaux, Martina Kovac, Daniel Shu, Katrijn Grupping, Laura Campora, Martine Douha, Thomas C. Heineman, Himal Lal

    Published 2017
    Connect to this object online.
    Book
    Save to List
    Saved in:
  3. 3
    A randomized phase 1/2 study of the safety and immunogenicity of a multivalent pneumococcal conjugate vaccine in healthy adults 50 through 85 years of age

    A randomized phase 1/2 study of the safety and immunogenicity of a multivalent pneumococcal conjugate vaccine in healthy adults 50 through 85 years of age by Brandon Essink, James Peterson, Kari Yacisin, Himal Lal, Sarah Mirza, Xia Xu, Ingrid L. Scully, Daniel A. Scott, William C. Gruber, Kathrin U. Jansen, Wendy Watson

    Published 2021
    Connect to this object online.
    Book
    Save to List
    Saved in:
  4. 4
    Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults

    Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults by Tino F. Schwarz, Stephanie Volpe, Gregory Catteau, Roman Chlibek, Marie Pierre David, Jan Hendrik Richardus, Himal Lal, Lidia Oostvogels, Karlis Pauksens, Stephanie Ravault, Lars Rombo, Gerard Sonder, Jan Smetana, Thomas Heineman, Adriana Bastidas

    Published 2018
    Connect to this object online.
    Book
    Save to List
    Saved in:
  5. 5
    Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials

    Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials by Lidia Oostvogels, Thomas C. Heineman, Robert W. Johnson, Myron J. Levin, Janet E. McElhaney, Peter Van den Steen, Toufik Zahaf, Alemnew F. Dagnew, Roman Chlibek, Javier Diez-Domingo, Iris S. Gorfinkel, Caroline Hervé, Shinn-Jang Hwang, Hideyuki Ikematsu, George Kalema, Himal Lal, Shelly A. McNeil, Tomas Mrkvan, Karlis Pauksens, Jan Smetana, Daisuke Watanabe, Lily Yin Weckx, Anthony L. Cunningham

    Published 2019
    Connect to this object online.
    Book
    Save to List
    Saved in:

Search Tools: